Profile data is unavailable for this security.
About the company
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
- Revenue in USD (TTM)24.99m
- Net income in USD-70.10m
- Incorporated2015
- Employees54.00
- LocationElutia Inc12510 PROSPERITY DRIVE, SUITE 370SILVER SPRING 20904United StatesUSA
- Phone+1 (240) 247-1143
- Fax+1 (510) 307-9896
- Websitehttps://elutia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey Medical Corp | 57.77m | -18.34m | 77.87m | 58.00 | -- | 9.92 | -- | 1.35 | -0.9276 | -0.9276 | 2.93 | 0.5271 | 0.889 | 2.16 | 6.19 | 996,051.80 | -28.22 | -- | -76.21 | -- | 57.32 | -- | -31.74 | -- | 1.03 | -13.65 | 0.6582 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 79.27m | 220.00 | -- | 0.3373 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.37m | 35.00 | 391.37 | 348.44 | -- | 35.44 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Assertio Holdings Inc | 125.76m | -68.49m | 90.57m | 53.00 | -- | 0.6941 | -- | 0.7202 | -0.7212 | -0.7212 | 1.32 | 1.37 | 0.3834 | 0.9052 | 2.34 | 2,372,887.00 | -20.88 | -21.51 | -30.33 | -32.05 | 70.31 | 88.68 | -54.46 | -62.10 | 1.57 | -- | 0.2293 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Scilex Holding Co | 50.83m | -171.53m | 108.28m | 113.00 | -- | -- | -- | 2.13 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -22.96m | 124.36m | 1.00 | -- | 281.32 | -- | -- | -0.8145 | -0.8145 | 0.00 | 0.0149 | 0.00 | -- | -- | 0.00 | -721.99 | -- | -1,752.70 | -- | -- | -- | -- | -- | -- | -2.06 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Puma Biotechnology Inc | 243.57m | 23.24m | 139.41m | 185.00 | 5.98 | 1.96 | 4.00 | 0.5724 | 0.475 | 0.475 | 5.03 | 1.45 | 1.15 | 17.91 | 5.83 | 1,316,589.00 | 10.95 | -12.21 | 18.85 | -20.53 | 69.29 | 78.78 | 9.54 | -11.79 | 1.40 | 3.61 | 0.5234 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Elutia Inc | 24.99m | -70.10m | 151.38m | 54.00 | -- | -- | -- | 6.06 | -3.05 | -2.86 | 1.12 | -2.28 | 0.5303 | 2.32 | 5.08 | 462,722.20 | -148.77 | -42.93 | -1,212.93 | -79.34 | 42.46 | 43.32 | -280.53 | -64.16 | 0.6842 | -0.6561 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| LifeVantage Corp | 196.01m | 4.13m | 161.95m | 217.00 | 40.51 | 5.83 | 21.33 | 0.8262 | 0.3192 | 0.3192 | 15.27 | 2.22 | 3.06 | 2.50 | 71.64 | 903,290.30 | 6.46 | 9.95 | 10.17 | 15.55 | 79.21 | 81.45 | 2.11 | 3.08 | 0.9923 | 559.36 | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
| Scpharmaceuticals Inc | 30.28m | -80.12m | 168.10m | 135.00 | -- | 5.48 | -- | 5.55 | -1.91 | -1.91 | 0.7417 | 0.6137 | 0.262 | 0.7268 | 4.52 | 224,281.50 | -69.31 | -38.23 | -78.18 | -42.31 | 69.72 | -- | -264.60 | -1,360.16 | 6.89 | -8.42 | 0.6246 | -- | -- | -- | -48.79 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 181.00m | 100.00 | -- | 8.72 | -- | 8.99 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Biostem Technologies Inc | 210.39m | 14.32m | 196.03m | 67.00 | 19.10 | 8.61 | 13.48 | 0.9317 | 0.6302 | 0.6302 | 10.58 | 1.40 | 3.82 | 8.46 | 5.01 | -- | 26.03 | -- | 135.75 | -- | 94.84 | -- | 6.81 | -- | 1.23 | 27.98 | 0.1576 | -- | -- | -- | -- | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.73m | 1.64bn | 203.24m | 166.00 | 0.1175 | 1.14 | 0.1235 | 117.21 | 119.47 | 119.47 | 0.0499 | 12.33 | 0.0058 | -- | 4.41 | 10,445.78 | 552.15 | -77.06 | 637.71 | -93.91 | -- | -- | 94,778.95 | -1,590.91 | -- | -45.76 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Data as of Nov 21 2024. Currency figures normalised to Elutia Inc's reporting currency: US Dollar USD
36.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 30 Sep 2024 | 2.86m | 9.63% |
| AIGH Capital Management LLCas of 30 Sep 2024 | 2.51m | 8.44% |
| SilverArc Capital Management LLCas of 11 Oct 2024 | 1.65m | 5.53% |
| Birchview Capital LPas of 30 Sep 2024 | 1.32m | 4.44% |
| Perkins Capital Management, Inc.as of 30 Sep 2024 | 856.55k | 2.88% |
| Alyeska Investment Group LPas of 30 Sep 2024 | 643.45k | 2.16% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 490.91k | 1.65% |
| Kennedy Capital Management LLCas of 30 Sep 2024 | 240.06k | 0.81% |
| Geode Capital Management LLCas of 30 Sep 2024 | 188.41k | 0.63% |
| EAM Investors LLCas of 30 Sep 2024 | 122.26k | 0.41% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
